Zinecard 250 mg (Dexrazoxane POWDER FOR SOLUTION) 250 MG

ZINECARD 250 MG is a powder for solution containing Dexrazoxane, used for specific medical conditions. This intravenous medication is manufactured by Pfizer Canada ULC.

Strength

250 MG

Pack Size

250MG/25ML VIAL

Manufacturer / TM Owner

PFIZER CANADA ULC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ZINECARD 250 MG is primarily used in medical settings to reduce the risk of cardiac toxicity associated with certain chemotherapy treatments. Dexrazoxane, the active ingredient, is often administered to patients undergoing specific cancer therapies. What is ZINECARD used for? It is typically prescribed to mitigate the potential heart-related side effects of anthracycline-based chemotherapy.

Side Effects

Common effects of ZINECARD 250 MG may include localized reactions at the injection site, such as redness or swelling. Some patients might experience nausea or fatigue. These effects are generally mild and temporary, but any persistent or severe reactions should be reported to a healthcare provider.

Precautions & Warnings

ZINECARD 250 MG should be handled with care, ensuring proper preparation and administration by trained medical professionals. It is important to follow all safety protocols when using this medication. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting treatment.

Avoid Interactions

ZINECARD 250 MG may interact with other medications, particularly those metabolized by the liver. It is crucial to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements might also affect the efficacy or safety of Dexrazoxane.

References

Frequently Asked Questions

ZINECARD 250 MG is used to reduce the risk of cardiac toxicity in patients undergoing certain chemotherapy treatments.

ZINECARD 250 MG is administered intravenously as a solution prepared from the powder.

Common side effects may include localized reactions at the injection site, nausea, and fatigue.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety.

ZINECARD 250 MG is manufactured by Pfizer Canada ULC.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.